Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354706 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1445688 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5706355 | 0.98 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5079153 | 0.98 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL27529254 | 0.98 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| Fumaric Acid SCHEMBL4955812 | 0.92 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| Fumaric Acid SCHEMBL4948911 | 0.92 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| Fumaric Acid SCHEMBL27529255 | 0.92 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27755779 | 0.87 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7056083 | 0.84 | DPP4 (0.35) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116298013-A | Identification method based on saliva metabonomics | 山东第一医科大学附属省立医院(山东省立医院) | 2023-06-23 | — | — | CN | claimed |
| CN-1784220-B | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG | 2011-08-03 | — | — | CN | claimed |
| CN-101837127-A | The application of glutaminyl and glutamate cyclase effector | PROBIODRUG AG | 2010-09-22 | — | — | CN | claimed |
| CN-101267838-A | Use of DPP-IV inhibitors to reduce hypoglycemic events | NOVARTIS AG (CH) | 2008-09-17 | — | — | CN | claimed |
| CN-101143217-A | Treatment of neurological and neuropsychological disorders | PROBIODRUG AG (DE) | 2008-03-19 | — | — | CN | claimed |
| CN-101095675-A | Dipeptidyl peptidase IV effectors | PROBIODRUG AG (GB) | 2008-01-02 | — | — | CN | claimed |
| CN-1321682-C | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2007-06-20 | — | — | CN | claimed |
| CN-1921856-A | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | claimed |
| CN-1278683-C | Use of dipeptidyl peptidase IV inhibitors for the treatment of anxiety | PROBIODRUG AG (DE) | 2006-10-11 | — | — | CN | claimed |
| US-7053055-B2 | Compounds of unstable DP IV-inhibitors | PROSIDION LTD. (GB) | 2006-05-30 | — | — | US | claimed |
| CN-1582149-A | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROBIODRUG AG (DE) | 2005-02-16 | — | — | CN | claimed |
| CN-1535681-A | Application of dipeptide base peptidase IV effector for reducing blood sugar level of mammal | ӡ��ҩƷ�ɷ�����˾ | 2004-10-13 | — | — | CN | claimed |
| CN-1132578-C | Use of dipeptidyl peptidase IV effectors to lower blood glucose levels in mammals | BIOLOG DRUG REAGENTS FOR PHARM (DE) | 2003-12-31 | — | — | CN | claimed |
| CN-1464881-A | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (CN) | 2003-12-31 | — | — | CN | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20250144291-A1 | ARTIFICIAL INTELLIGENCE BASED IMPLANTABLE DRUG DELIVERY SYSTEM | Manta Implant LLC (US) | 2025-05-08 | — | — | US | disclosed |
| CN-1216468-A | Use of dipeptidyl peptidase IV effectors to lower blood glucose levels in mammals | BIOLOG DRUG REAGENTS FOR PHARM (DE) | 1999-05-12 | — | — | CN | disclosed |
| EP-0896538-A1 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR LOWERING THE BLOOD GLUCOSE LEVEL IN MAMMALS | Probiodrug Gesellschaft für Arzneimittelforschung mbH (DE) | 1999-02-17 | — | — | EP | disclosed |
| WO-1997040832-A1 | USE OF DIPEPTIDYL PEPTIDASE IV EFFECTORS FOR LOWERING THE BLOOD GLUCOSE LEVEL IN MAMMALS | Probiodrug Gesellschaft für Arzneimittelforschung mbH (DE) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | DPP4 798/4885DPP8 521/4885DPP9 617/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | DPP4 911/4885DPP8 697/4885DPP9 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.